KZIA Kazia Therapeutics Ltd

Novogen Granted U.S. Patent Covering Phenoxodiol for Cancer Treatment STAMFORD, Conn., Nov. 19 /PRNewswire-FirstCall/ -- Pharmaceutical company Novogen , has been granted the U.S. patent covering methods for treating all benign and malignant cancers with the anti-cancer drug phenoxodiol, including ovarian cancer, breast cancer, prostate cancer and cervical cancer. Phenoxodiol is currently in phase II human clinical trials in the U.S. and Australia, and the rights to commercialize phenoxodiol have been licensed to the Novogen majority-owned U.S. company Marshall Edwards, Inc. Managing Director of Novogen, Mr. Christopher Naughton, said the latest patent joined a suite of existing protection which consolidated and further secured Novogen's intellectual property position. Novogen has a leading position in the research and development of drugs derived from its phenolic technology platform. The Company manages its international research and development programs using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and other key international locations. The oncology compound phenoxodiol is being developed by the Company's listed subsidiary Marshall Edwards, Inc. (LSE-AIM: MSH). More information on phenoxodiol and on the Novogen group of companies can be found at http://www.marshalledwardsinc.com/ and http://www.novogen.com/ . Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials. After the results of these trials are submitted in a new drug application to the FDA, the FDA must approve the drug as safe and effective before marketing can take place. Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). DATASOURCE: Novogen Limited CONTACT: Warren Lancaster of Novogen, +1-203-327-1188 Web site: http://www.novogen.com/ http://www.marshalledwardsinc.com/

Copyright